Skip to main content

Musculoskeletal Diseases

1
Pipeline Programs
5
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Biocorp
BiocorpFrance - Issoire
1 program
1
CholecalciferolPhase 41 trial
Active Trials
NCT06508242Unknown80Est. Dec 2025
Temple Therapeutics
Temple TherapeuticsNetherlands - Geleen
2 programs
Early Direct Access Physical TherapyN/A1 trial
Physical TherapistN/A1 trial
Active Trials
NCT02272257Unknown150Est. Apr 2018
NCT02522923Unknown150Est. Jan 2020
Medacta
MedactaSwitzerland - Castel San Pietro
1 program
NextAR TKA systemN/A1 trial
Active Trials
NCT04844879Completed40Est. Jun 2024
Merck & Co.
Merck & Co.RAHWAY, NJ
1 program
ACE-083PHASE_11 trial
Active Trials
NCT02257489Completed58Est. Apr 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
BiocorpCholecalciferol
Merck & Co.ACE-083
MedactaNextAR TKA system
Temple TherapeuticsPhysical Therapist
Temple TherapeuticsEarly Direct Access Physical Therapy

Clinical Trials (5)

Total enrollment: 478 patients across 5 trials

NCT06508242BiocorpCholecalciferol

Effects Of Vitamin D On Bone, Muscle, And Adipose Tissue In Obese Subjects

Start: Apr 2023Est. completion: Dec 202580 patients
Phase 4Unknown
NCT02257489Merck & Co.ACE-083

Phase 1 Study of ACE-083 in Healthy Subjects

Start: Sep 2014Est. completion: Apr 201658 patients
Phase 1Completed
NCT04844879MedactaNextAR TKA system

Medacta NextAR TKA Pivotal Trial

Start: May 2021Est. completion: Jun 202440 patients
N/ACompleted
NCT02522923Temple TherapeuticsPhysical Therapist

Back-on-Track Studying Early Quality Care

Start: Jan 2019Est. completion: Jan 2020150 patients
N/AUnknown
NCT02272257Temple TherapeuticsEarly Direct Access Physical Therapy

Temple University Employees With Musculoskeletal Conditions Receive Physical Therapy to Treat Limitations Early

Start: Apr 2015Est. completion: Apr 2018150 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.